Abstract:Breast cancer is one of the most common malignant tumors in women. Despite the continuous improvement of current diagnosis and treatment technologies and the increasing proportion of early breast cancer in the new cases of breast cancer, local advanced breast cancer (LABC) is still a prominent clinical problem. LABC has become an important factor affecting the treatment effect of breast cancer due to its low overall survival rate, high recurrence rate and distant metastasis rate. Radiotherapy, including preoperative radiotherapy and postoperative radiotherapy, is currently recognized as an effective treatment that can control the metastasis of breast cancer and improve the survival rate of breast cancer patients. However, there are few clinical studies on preoperative radiotherapy. Preoperative radiotherapy is known to reduce tumor diameter, make tumor tissue and surrounding normal tissue fibrosis and prevent intraoperative tumor spread, which can improve the quality of life of LABC patients. In this paper, the research status of LABC and preoperative radiotherapy of LABC are reviewed.
杨思琦 宋启斌 龚虹云. 局部晚期乳腺癌术前放疗研究进展[J]. 中国医药导报, 2019, 16(23): 41-44.
YANG Siqi SONG Qibin GONG Hongyun. Reserch progress of preoperative radiotherapy for locally advanced breast cancer. 中国医药导报, 2019, 16(23): 41-44.
[1] 金性江.晚期乳腺癌的放射治疗[J].中国肿瘤临床,1983, 20(1):15-18.
[2] Ma J,Song J,Chen H,et al. Intraarterial interventional therapy for inoperable local advanced breast cancer:a retrospective study [J]. Oncol Lett,2018,15(2):1955-1962.
[3] Alkhanbashi M,Caramuta S,Alajmi AM,et al. Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment [J]. PLoS One,2016,11(4):e0152032.
[4] Lisa H. Breast cancer:Challenges,controversies,breakthroughs [J]. Nat Rev Clin Oncol,2010,7(12):669-670.
[5] Chen W,Zheng R,Baade PD,et al. Cancer statistics in China,2015 [J]. Ca Cancer J Clin,2016,66(2):115-132.
[6] Rustogi A,Budrukkar A,Dinshaw K. Management of locally advanced breast cancer:Evolution and current practice [J]. J Cancer Res Ther,2005,1(1):21-30.
[7] Lehmann BD,Bojana J,Xi C,et al. Refinement of Triple-Negative Breast Cancer Molecular Subtypes:Implications for Neoadjuvant Chemotherapy Selection [J]. PLoS One,2016,11(6):e0157368.
[8] 乔伟强,潘淋淋,寇长贵,等.局部晚期乳腺癌新辅助化疗病理完全缓解与预后相关性的Meta分析[J].中国老年学杂志,2016,36(16):3982-3985.
[9] Gradishar WJ,Anderson BO,Balassanian R,et al. Breast Cancer Version 2,2015 [J]. J Natl Compr Canc Netw,2015, 13(4):448-475.
[10] Kinoshita S,Fukushima N,Miyake R,et al. Clinicopathological Assessment of Patients with Locally Advanced Breast Cancer with 10 or More Lymph Node Metastases [J]. Breast Can Curr Res,2016,1:107.
[11] Carrara GFA,Scapulatemponeto C,Abrah?觔o M,et al. Breast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up [J]. Clinics,2017,72(3):134-142.
[12] Senkus E,Kyriakides S,Ohno S,et al. on behalf of the ESMO Guidelines Committee. Primary breast can- cer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up [J]. Ann Oncol,2015,26 (Suppl 5):v8-v30.
[13] Liu J,Su M,Hong S,et al. Nomogram predicts survival benefit from preoperative radiotherapy for non-metastatic breast cancer:A SEER-based study [J]. Oncotarget,2017, 8(30):49 861-49 868.
[14] 黄一容,汪绍训.乳腺癌手术前放射治疗的探讨[J].北京大学学报:医学版,1964(2):134-137.
[15] Lacerda L,Pusztai L,Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer:implications for future therapeutic approaches [J]. Drug Resist Updat,2010,13(4-5):99-108.
[16] Wolfe AR,Woodward WA. Breast Cancer Stem Cell Correlates as Predicative Factors for Radiation Therapy [J]. Semin Radiat Oncol,2015,25(4):251-259.
[17] Fu W,Sun H,Zhao Y. Trends and outcomes of neoadjuvant radiotherapy compared with postoperative radiotherapy for malignant breast cancer [J]. Oncotarget,2018,9(36):24 525-24 536.
[18] 赵晨.术前放疗用于能手术的乳腺癌[J].国际肿瘤学杂志,1979,6(5):223.
[19] 王坚.对Ⅲ期乳腺癌患者进行术前放化疗的效果研究[J].当代医药论丛,2015,22(9):296.
[20] 赵静,刘刚,许梅,等.大分割三维适形放疗(3DCRT)局部晚期非小细胞肺癌的临床研究[J].医药前沿,2015,5(23):204-205.
[21] 荣庆林,王淑莲,唐玉,等.局部晚期乳腺癌新辅助化疗和改良根治术后放疗价值分析[J].中华放射肿瘤学杂志,2017,26(8):884-891.
[22] National Comprehensive Cancer Network. Breast cancer [M]. Version 2,2017.
[23] Chadhia M,Bailey L,Dutton SC,et al. Locally advanced breast cancer (online publication) [M]. American College of Radiology (ACR),2016.
[24] Kaae S. The prognostic significance of early diagnosis in breast cancer:a study of the early symptoms and their duration before the patients come under treatment [J]. Acta Radiologica,1948,29(6):475.
[25] Riet FG,Fayard F,Arriagada R,et al. Preoperative radiotherapy in breast cancer patients:32 years of follow-up [J]. Eur J Cancer,2017,76:45-51.
[26] 张永禄,陈祖培.可手术乳癌术前放疗的评价[J].国际医学放射学杂志,1981,14(3):192-193.
[27] Moss WT. Therapeutic Radiology [J]. The C.V.Mosby Company,1959:175.
[28] Coles CE,Fourquet A,Poortmans P. Preoperative radiation therapy:The ‘new’ targeted breast cancer treatment? [J]. Eur J Cancer,2017,78:116-117.
[29] Pajonk F,Vlashi E,McBride WH. Radiation resistance of cancer stem cells:the 4 R′s of radiobiology revisited [J]. Stem Cells,2010,28(4):639-648.